38 results about "Immunological memory" patented technology

The present invention discloses fusion proteins of the immunodominant antigens ESAT-6 and Ag85B from Mycobacterium tuberculosis or homologues thereof, and a tuberculosis vaccine based on the fusion proteins, which vaccine induces efficient immunological memory.

Streptococcus pneumoniae is a major cause of pneumoniae, meningitis, and major cause of morbidity and mortality throughout the world by bacterial otitis media, pneumoniae, meningitis, and bacteraemia. It is an important agent of disease in man especially among infants, the elderly and immunocompromised persons. The present invention provides a solution to this problem by providing a substantially pure or isolated disease related antigen selected from the group consisting of the isolated, recombinant or synthetic S. pneumoniae human immunogenic antigens of SP_0562, SP_0965, SP_0082 (in particular the fragments SP4 and SP 17 of said SP_0082), and a Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386), or a fragments thereof or substantially identical antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or against S. pneumoniae in a human. In a particular embodiment, the present invention provides an isolated, recombinant or synthetic S. pneumoniae Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386) as a disease related antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or for use in the treatment of an S. pnewnoniae infection in a human. It further provides antibodies that specifically bind to the S. pneumoniae disease related antigens identified herein for use in the treatment of a an S. pneumoniae infection in a human, such as for example in a treatment to induce immunological memory in a human against S. pneumoniae, i.e. in a vaccination treatment of S. pneumoniae. It is also an aspect of the present invention to provide the use of any one of the S. pneumoniae disease related antigens as identified herein, or of the antibodies specific for said antigens in methods to diagnose for a S. pneumoniae disorder in a human.

The invention discloses a logistic distribution partitioning balance optimizing method, which builds a logistic distribution partitioning multipurpose optimal model and designs immune algorithm solving. A model minimizes zone line number as well as the total distance and the total working time of all lines to balance the line number, the total distance, the total working time and the total demanded quantity of different zones. The model adopts VRP, TSP and a shortest path algorithm to ensure the optimization of a distribution path while balancing zones. An arithmetic operator and a mechanism aroused by designed immunity comprise clonal selection, high-frequency variation, immune clearance and immunological memory, and two stages are searched to solve by the synergy of the construction and the zone of the initial partitioning scheme. The method of the invention is suitable for the partitioning balance optimization of large-scale logistic distribution, and can lower logistic distribution cost, improve logistic distribution efficiency and improve the degree of satisfaction of customers to staff.

The invention discloses a robot path planning method. A direction operator is introduced on the basis of an artificial fish swarm algorithm to improve the accuracy and the success rate of fish swarm behaviors such as clustering, tailgating and even foraging, and an immunological memory operation is added to improve the global searching capability of the algorithm and reduce the probability of local extreme values. Simulation experiments in two typical grid map environments show that compared with a fast genetic algorithm and an artificial fish swarm algorithm, the immunological-directional artificial fish swarm algorithm has the advantages of better result stability, shorter calculation time and feasible solution closer to the optimal path.

The invention belongs to the technical field of virtual machines in cloud and discloses a multi-objective virtual machine adaptive position selection method and a distributed cloud system. By adoptinga fuzzy logic control parameter and using a fitness function of multi-dimensional cooperation, a search space of solving is optimized; based on a biological immunological memory mechanism, ordered coding is performed for populations according to groups and resources in a position selection process, and population updating is performed in combination with an epsilon dominant elitist strategy; anda tournament selection method is used during population selection, and the populations are subjected to optimization processing through a single-point operator crossover mechanism and an X point variation operation. For verifying the performance of an algorithm, PHM, NSG-2, DRF and MOVMLSA algorithms are subjected to simulation experiment; and an experiment result shows that the immune operator-based multi-objective virtual machine position selection algorithm has great advantages in aspects of resource utilization rate, physical machine load balance degree, unit resource cost and the like.

The present invention discloses a method of inhibiting CD8+ T cell deletion by the liver via the use of Toll-like receptor-4 inhibitors. Also disclosed are compositions of Toll-like receptor-4 inhibitors and either immunogenic agents or activated CD8+ T cells, which can be used to enhance secondary immune responses in normal and immunocompromised subjects. The administration of Toll-like receptor-4 inhibitors, alone or in combination with one or both of immunogenic agents or activated CD8+ T cells, to subjects to enhance secondary immune responses is also disclosed.

The structural design, preparative methods and chemical composition of two structural formulations of bivalent vaccines against morphine-heroin addiction (morphine-6-hemisuccinyl-EDC-TFCS-tetanus toxoid and 3-O-carboxymethylmorphine-EDC-TFCS-tetanus toxoid), are disclosed. These vaccines are suitable for human use in which they are capable of triggering the synthesis of polyclonal antibodies against morphine opiate and its structural analogue, heroin, through the repeated in vivo administration of these formulations, in active vaccination protocols, in pre-clinical studies in rodents. The active vaccination paradigm through which these immunogens trigger a humoral immune response consolidated with a long-term immunological memory, characterized by the presence of high titers of specific antibodies against these two drugs of abuse, is also disclosed. Furthermore, the present invention reveals the efficacy of these conjugate formulations for triggering a sustained immunoprotection against morphine and heroin addiction using an intravenous self-administration paradigm of these two opiate substances in the rodent. Finally, a discussion is also made on the potential future use of these immunoconjugates in active vaccination protocols for treating both morphine and heroin addiction in the humans.

Methods of monitoring and measuring dynamic adaptive immune cell responses are provided. High-throughput sequencing of T cell receptor and immunoglobulin loci is used to characterize the breadth of an effector cell response to a stimulus, such as a vaccine or infection. Unique responding effector cell clones and abundance thereof can be determined. Additionally, methods for determining the contribution of responding effector cells to the immunological memory compartment are provided.

The structural design, preparative methods and chemical composition of two structural formulations of bivalent vaccines against morphine-heroin addiction (morphine-6-hemisuccinyl-EDC-TFCS-tetanus toxoid and 3-O-carboxymethylmorphine-EDC-TFCS-tetanus toxoid), are disclosed. These vaccines are suitable for human use in which they are capable of triggering the synthesis of polyclonal antibodies against morphine opiate and its structural analogue, heroin, through the repeated in vivo administration of these formulations, in active vaccination protocols, in pre-clinical studies in rodents. The active vaccination paradigm through which these immunogens trigger a humoral immune response consolidated with a long-term immunological memory, characterized by the presence of high titers of specific antibodies against these two drugs of abuse, is also disclosed. Furthermore, the present invention reveals the efficacy of these conjugate formulations for triggering a sustained immunoprotection against morphine and heroin addiction using an intravenous self-administration paradigm of these two opiate substances in the rodent. Finally, a discussion is also made on the potential future use of these immunoconjugates in active vaccination protocols for treating both morphine and heroin addiction in the humans.

The invention discloses a nucleic acid and recombinant protein co-immune vaccine based on a classical swine fever virus gene as well as a preparation method and application of the co-immune vaccine. The preparation method comprises the steps that firstly, optimized recombinant plasmids and recombinant classical swine fever vaccine antigen protein are obtained by combining gene engineering and cellengineering; then the nucleic acid sequence and the recombinant protein are compounded into different liquid phase layers of a biphasic adjuvant, so that the obtained co-immune vaccine is good in immunogenicity and short in immune blank period, can rapidly induce an organism to generate high-level, high-affinity and durable antibody response and immune memory, effectively protects a target animalfrom being attacked by classical swine fever virulent viruses, and the method can be applied to preparation of products for preventing / treating classical swine fever.

An object of the present invention is to provide a peptide vaccine for preventing and / or treating diseases caused by amyloid β-peptide, such as Alzheimer's disease. The present invention solves the above object by providing a peptide vaccine constructed by inserting a peptide having an amino acid sequence of a cell attachment motif of a cell adhesive molecule to a peptide which consists of a peptide having an amino acid sequence of multiagretope type T-cell epitope, which has been generated immunological memory, or a peptide including the same; an linker peptide; and a peptide having an amino acid sequence of a B cell epitope which is a specific region of amyloid β-peptide or a peptide including the same.

An object of the present invention is to provide a peptide vaccine for preventing and / or treating diseases caused by amyloid β-peptide, such as Alzheimer's disease. The present invention solves the above object by providing a peptide vaccine constructed by inserting a peptide having an amino acid sequence of a cell attachment motif of a cell adhesive molecule to a peptide which consists of a peptide having an amino acid sequence of multiagretope type T-cell epitope, which has been generated immunological memory, or a peptide including the same; an linker peptide; and a peptide having an amino acid sequence of a B cell epitope which is a specific region of amyloid β-peptide or a peptide including the same.

The invention discloses application of C-type CpG M362 in HBV preventive and therapeutic vaccines as an adjuvant and a preparation method of the HBV preventive and therapeutic vaccines. Compared withthe traditional HBV preventive vaccines, the HBV preventive vaccines taking the CpG M362 as the adjuvant have the maximum advantages that an organism can be induced to generate high-level body fluid response, and the cell response of the organism can be enhanced. Meanwhile, by applying the HBV therapeutic vaccines taking the CpG M362 as the adjuvant into clinical HBV treatment, a hepatic immunosuppression microenvironment caused by chronic HBV infection can be improved, immune tolerance caused by the HBV infection can be reversed, the cell response and body fluid response of the organism can be enhanced, and thus, HBV is completely cleared out. More importantly, after immunization of the vaccines taking the CpG M362 as the adjuvant, the organism can be induced to form long-term immunological memory, the organism can be protected from HBV reinfection, and a novel effective policy is provided for the clinical prevention of the HBV and the treatment of chronic HBV.

The present invention provides an antibody or fragment thereof that expresses an activated receptor (OX40) on the surface of activated CD4+T, CD8+T cells, and the use of the antibody or fragment thereof for the prevention or treatment of diseases. The antibody disclosed by the invention is high in affinity to OX40 and obvious in effect of activating an OX40 signal channel; the antibody has a relatively broad-spectrum immunopotentiation effect, and can enhance T cell response immune memory; and good tumor inhibiting and killing effects are achieved in animal model in-vivo experiments, and good clinical application prospects are achieved.

The invention relates to the technical field of cell culture, in particular to a tumor neoantigen specific tumor infiltration lymphocyte co-culture method which is characterized by comprising the following steps: S1, tumor neoantigen preparation: respectively collecting the tissues of lung cancer (N1), pancreatic cancer (N2), bile duct cancer (N3), triple-negative breast cancer (N4) and melanoma tumor (N5), separating tumor cells, andcollecting normal tissues of corresponding individuals; comparing the all-exon sequencing and normal tissue and tumor tissue sequencing results to determine all amino acid mutations, then designing a gene construct containing all mutant peptide sequences and synthesizing a long-chain polypeptide according to a neoantigen coded by a mutant gene. The TIL cells harvested by designing a co-culture method of tumor neoantigen specific tumor infiltration lymphocytes can effectively kill autologous tumor target cells, can induce immune cells to have multiple target spots, are free of limitation of cancer species, and have an immune memory effect.

The invention provides an antigen and adjuvant co-delivery nano vaccine based on protamine as a carrier. The nano vaccine comprises a carrier, an antigen and an adjuvant, wherein the carrier is protamine sulfate; The invention also provides a preparation method and application of the vaccine. The nano vaccine prepared by the invention can effectively improve uptake efficiency of antigen presentingcells on antigens and adjuvants, efficiently stimulate maturation of the antigen presenting cells, assist the antigens in realizing cross presentation, significantly improve in-vivo transfer efficiency of the antigens and the adjuvants, stimulate a body to produce high-efficiency humoral immunity and cellular immunity, and at the same time produce an immune memory effect. In-vivo treatment is carried out on mouse subcutaneous melanoma, and it is proved that the nano vaccine has a good anti-tumor immunotherapy effect. The nano vaccine is simple in structure, convenient to prepare and excellentin immunotherapy performance, and has good application potential.

Described are cell-based cancer vaccines and anti-cancer immunotherapies. The vaccines include isolated tumor cells activated with one or more genotoxic drugs, and, optionally, treated with one or more MK2 inhibitors. The activated cells are highly immunogenic non-proliferative cells, and may be tested for immunogenicity ex vivo for priming T cells by co-incubating the isolated activated cells with dendritic cells and T cells. The vaccines are typically administered into patient's tumor to provide an intratumoral immune activation. Immune checkpoint inhibitor(s) (ICI) may be administered before, during, or after vaccine administration. ICI may be a component of the vaccine. The vaccines confer heightened cytotoxic immune response against the cancer cells, induce tumor regression, and enhance survival from cancer. The vaccines prevent tumor recurrence and induce a long-lasting anti-tumor immunological memory.

The invention discloses a steam pipeline leakage identification method and device, a storage medium and terminal equipment, and the method comprises the steps: obtaining a topological network structure of a pipeline, and determining a rule according to a preset numerical value, and obtaining a central value and a weight value of the topological network structure as initial antibodies; performing iterative computation on all the initial antibodies according to parameters of a preset immune genetic algorithm, so as to update a current fitness function through an error obtained by an RBF neural network algorithm in each iterative computation, and then performing evolutionary operation on all the initial antibodies according to the updated fitness function, so as to obtain an evolutionary result of all the initial antibodies; updating the immune memory cells according to all initial antibodies after evolution operation until the number of iterations reaches a preset value to obtain a plurality of iterative antibodies; and outputting a pipeline leakage prediction result according to the plurality of iterative antibodies. Compared with the prior art, the method can improve the accuracy and recognition efficiency of pipeline steam detection.

Formulations and preparations having immune memory enhanced properties are disclosed that provide for enhancing immune response against a tumor growth, cancer, infectious agent, bacteria, virus or other infectious or non-infectious agent. The vaccine formulation includes an immune memory invoking component, such as an antigen of an infectious agent, virus (e.g., Rabies), bacteria, prion, neo-antigen or other moiety antigen, and a targeted antigen (e.g., a harvested tumor tissue (B-cell, T-cell, epitopes)). The vaccine formulation / preparations may comprise a target infectious agent protein / peptide component (such as a SARS-Cov-2 spike protein epitope) mixed with, or fused to (or otherwise conjugated) an immune-memory associated viral antigen (such as Rabies, polio, or other peptide / protein antigen or peptide or fragment thereof).

The invention discloses a Golgi apparatus and genetic engineering exosome hybrid membrane coated retinoic acid in-situ spray hydrogel vaccine as well as a preparation method and an application thereof, and belongs to the technical field of medicines. In particular to a retinoic acid in-situ spray hydrogel vaccine which inhibits exosome PD-L1 secretion, reproduces lymph node immune cells to trigger immune memory so as to activate systemic immune response and is coated with a Golgi apparatus and genetic engineering exosome hybrid membrane and an application of the retinoic acid in-situ spray hydrogel vaccine in inhibition and / or treatment of postoperative recurrence of melanoma.

The invention provides application of an SUMF2 gene in preparation of a medicine for preventing allergic asthma attack and reducing airway hyperresponsiveness and belongs to the technical field of biomedicine. According to the application, a bioinformatics technology and an animal experiment verify that abnormality of a metabolic pathway of an SUMF1 / 2-glycosaminoglycan enables epithelial cells to generate an immune-memory-similar phenomenon, and a TH2 reaction can be promoted when the SUMF1 / 2-glycosaminoglycan is in contact with allergens again. According to the application, 20 days before asthma is induced, an adeno-associated virus vector is utilized to over-express the SUMF2 gene derived from epithelial cells of an airway of a mouse, and compared with a control group, the airway inflammatory response of lungs of asthmatic mice can be obviously improved. Therefore, the overexpressed SUMF2 can be used as a genetherapy target for preventing allergic asthma and reducing the airway hyperresponsiveness. Therefore, the use of the adeno-associated virus for overexpression of the SUMF2 in the field of prevention of the allergic asthma has a wide application value and a broad market prospect.

The invention belongs to the field of biological medicines, and relates to a novel virus immunotherapy drug compound, in particular to an application of the virus immunotherapy medicine compound in preparation of a medicine for treating HBV infection, the virus immunotherapy medicine compound is composed of an antiviral medicine, an immunomodulatory medicine and a recombinant hepatitis B vaccine,virus replication is inhibited through the antiviral medicine, and then immunization is conducted in the mode of adding the immunomodulatory agent and the vaccine. An effective immune memory protection reaction is established for organisms, strong antibody protection and cellular immunity are generated, virus recurrence is prevented, a purpose of removing viruses is even achieved, and HBV reinfection is prevented. Compared with an existing antiviral immune medicine, the novel virus immunotherapy drug compound is safe and effective and can be used for clinically treating virus infection diseases.

The invention provides a network anomaly detection method based on an artificial immunity principle belonging to information safety field. The invention implements the network anomaly detection method capable of fast detecting with high detection accuracy by simulating biological immune system response to external antigen, training antigen data collection and artificial immune system study, and detecting network anomaly. The network anomaly detection method has superior characteristics of a non-linearity of the biological immune system, cloning selection, immune network and immunological memory, solves the problems of low detection speed and low detection accuracy in the present network anomaly detection. The invention also applies to the pattern recognition, machine learning fields and has wide application prospect.

The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula I and / or Formula II, preferably Compound 1 or its derivative, salt, tautomeric form, isomer, polymorph, solvate, or intermediates thereof. The method of inducing an immune response in a mammal is mediated through immune memory. The present invention also provides for such platinum based compounds and their use in treating cancer, metastasis or cancer relapse.

The invention discloses a robot path planning method. Based on the artificial fish swarm algorithm, a direction operator is introduced to improve the accuracy and success rate of fish swarming behaviors such as swarming, chasing, and even foraging, and immune memory operations are added to improve the algorithm. global search capabilities and reduce the probability of local extreme values. Simulation experiments in two typical raster map environments show that this immune-directional artificial fish swarm algorithm has better result stability and shorter calculation time than the fast genetic algorithm and the conventional artificial fish swarm algorithm. and a feasible solution closer to the optimal path.

The invention discloses an intelligent immune self-healing method and system for a ship regional distribution power system. The method comprises the following steps of detecting a fault of the ship regional distribution power system, generating an intelligent immune self-healing scheme of the ship regional distribution power system, and enabling the ship regional distribution power system to intelligently execute fault recovery. The ship regional distribution electric power immune system has memory ability, the generated fault characteristics are recorded through the immune memory ability of B cells, and the fault can be quickly identified when occurring again. And a ship regional distribution power system fault self-healing global optimal scheme can be rapidly obtained. The ship regional distribution electric power immune system has a diversity maintaining capability, and in order to deal with various faults, the diversity of antibody groups is maintained by inhibiting antibodies with too high concentration, and the global convergence of an algorithm is ensured.

The invention discloses an adjuvant-free single-dose HBsAg nanogel vaccine and a preparation method thereof. The preparation method of the adjuvant-free single-dose HBsAg nanogel vaccine comprises the following step: under a constant-temperature stirring condition, mixing CS, HBsAg and a gamma-PGA solution step by step to prepare the positive-charge or negative-charge adjuvant-free single-dose HBsAg nanogel vaccine. The positive-charge HBsAg nanogel vaccine can obtain effective antibody expression only by single-dose injection, so that the immunity of cells is enhanced, the compliance of a vaccinator can be better improved, and general implementation of HBV prevention is guaranteed. The adjuvant-free single-dose HBsAg nanogel vaccine can induce formation of immunological memory to perform long-acting immunity protection on the vaccinator. The negative-charge HBsAg nanogel vaccine has no obvious generation of antibodies through single-dose injection, but when applied in combination with the positive-charge HBsAg nanogel vaccine, can obtain stronger cell immunity, and can better perform long-acting immunity protection on HBV.

The invention discloses application of C-type CpG M362 in HBV preventive and therapeutic vaccines as an adjuvant and a preparation method of the HBV preventive and therapeutic vaccines. Compared withthe traditional HBV preventive vaccines, the HBV preventive vaccines taking the CpG M362 as the adjuvant have the maximum advantages that an organism can be induced to generate high-level body fluid response, and the cell response of the organism can be enhanced. Meanwhile, by applying the HBV therapeutic vaccines taking the CpG M362 as the adjuvant into clinical HBV treatment, a hepatic immunosuppression microenvironment caused by chronic HBV infection can be improved, immune tolerance caused by the HBV infection can be reversed, the cell response and body fluid response of the organism can be enhanced, and thus, HBV is completely cleared out. More importantly, after immunization of the vaccines taking the CpG M362 as the adjuvant, the organism can be induced to form long-term immunological memory, the organism can be protected from HBV reinfection, and a novel effective policy is provided for the clinical prevention of the HBV and the treatment of chronic HBV.